-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CQpJuAbKPWMtPEw/LyaHm1LJVtlDlyY2H2adzWLbeyEf6hLOxxDHcm/htxmoU0wK
 hrZvRZ9q9VUQhQQY0P9SWg==

<SEC-DOCUMENT>0001209191-10-006587.txt : 20100203
<SEC-HEADER>0001209191-10-006587.hdr.sgml : 20100203
<ACCEPTANCE-DATETIME>20100203162542
ACCESSION NUMBER:		0001209191-10-006587
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20100201
FILED AS OF DATE:		20100203
DATE AS OF CHANGE:		20100203

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pernock David
		CENTRAL INDEX KEY:			0001471956

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31564
		FILM NUMBER:		10571001

	MAIL ADDRESS:	
		STREET 1:		405 EAGLEVIEW BOULEVARD
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Fibrocell Science, Inc.
		CENTRAL INDEX KEY:			0000357097
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870458888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		405 EAGLEVIEW BOULEVARD
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341
		BUSINESS PHONE:		484-713-6000

	MAIL ADDRESS:	
		STREET 1:		405 EAGLEVIEW BOULEVARD
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISOLAGEN INC
		DATE OF NAME CHANGE:	20020320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN FINANCIAL HOLDING INC /DE
		DATE OF NAME CHANGE:	19960330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN FINANCIAL HOLDING INC /CO
		DATE OF NAME CHANGE:	19921008
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>c95379_4x0.xml
<DESCRIPTION>MAIN DOCUMENT DESCRIPTION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2010-02-01</periodOfReport>

    <issuer>
        <issuerCik>0000357097</issuerCik>
        <issuerName>Fibrocell Science, Inc.</issuerName>
        <issuerTradingSymbol>FCSC.OB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001471956</rptOwnerCik>
            <rptOwnerName>Pernock David</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O 405 EAGLEVIEW BOULEVARD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>EXTON</rptOwnerCity>
            <rptOwnerState>PA</rptOwnerState>
            <rptOwnerZipCode>19341</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.08</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2010-02-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1650000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2020-02-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1650000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2100000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The 1,650,000 options vest as follows: (i) 250,000 shares on February 1, 2010; (ii) 100,000 shares upon the closing of a strategic partnership or licensing deal with a major partner that enables Fibrocell Science, Inc. (the &quot;Company&quot;) to significantly improve and/or accelerate its capabilities in such areas as research, production, marketing and/or sales and enable the Company to reach or exceed its major business milestones within the Company's strategic and operational plans, provided Mr. Pernock is the CEO on the closing date of such partnership or licensing deal; and (iii) 1,300,000 shares in equal 1/36th installments monthly over a three-year period, provided Mr. Pernock is the CEO on each vesting date.</footnote>
        <footnote id="F2">Options issued pursuant to the employment agreement between the Company and Mr. Pernock dated February 1, 2010.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>David Pernock</signatureName>
        <signatureDate>2010-02-01</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----